Intravitreal injection versus medical treatment for acute CSR - Trial PACTR202204601902304
Access comprehensive clinical trial information for PACTR202204601902304 through Pure Global AI's free database. This Phase 3 trial is sponsored by Suez Canal University Hospital and is currently Recruitment Completed. The study focuses on Eye Diseases.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
drug
Sponsor & Location
Suez Canal University Hospital
Moataz A. Sallam
Timeline & Enrollment
Phase 3
Nov 01, 2021
May 15, 2022
Summary
Central serous chorioretinopathy (CSCR) is a condition occurring in young adults, especially males in their twenties to fifties, who exhibit acute or subacute central visual loss or distortion. It is an idiopathic disorder characterized by a localized serous detachment of the sensory retina at the macula secondary to leakage from the choriocapillaris in association with retinal pigment dysfunction. Different treatment options are available including observation, photodynamic therapy, laser photocoagulation, micropulse diode laser and intravitreal anti VEGF agents. So, this study is designed to evaluate the efficacy and safety of intravitreal ranibizumab or aflibercept versus medical therapy with oral spironolactone for treatment of patients with acute central serous chorioretinopathy.
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR202204601902304
Non-Device Trial